New Alzheimer’s Drug Approved

On July 2, it was announced that the U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s drug Donanemab for patients with early symptomatic Alzheimer’s disease or mild cognitive impairment.  This drug has been given the brand name, Kisunla.

Kisunla is administered once each month as an intravenous infusion. A neurologist specializing in Alzheimer’s disease and related disorders is the best resource for evaluating the potential benefits of this treatment.

A new treatment for early-stage disease or mild cognitive impairment supports Alzheimer’s Community Care’s advocacy for routine cognitive screening and early intervention.

Call 561-683-2700 or email our Education Department for more information: Education@alzcare.org.